Biotech entity
All 1 tracked stories fall under one category: gene-therapy. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Center for Biologics Evaluation and Research (CBER), all published on February 23, 2026.
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: gene-therapy. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Center for Biologics Evaluation and Research (CBER), all published on February 23, 2026. Each carries 8 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Center for Biologics Evaluation and Research (CBER). Shared-story counts are live from our verified record — not editorial picks.
First Approvals
Anticipated first wave of gene therapy approvals under the new streamlined framework.
Framework Formalized
FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
Draft Guidance Issued
FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
START Pilot Launch
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.
Center for Biologics Evaluation and Research (CBER) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
